

**Brilliant Violet 605™ anti-human CD185 (CXCR5)**

**Catalog # / Size:** 2384645 / 25 tests  
2384650 / 100 tests

**Clone:** J252D4

**Isotype:** Mouse IgG1, κ


**Immunogen:** Human CXCR5-transfected cells

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** 0.5




Human peripheral blood lymphocytes were stained with CD19 APC and CD185 (clone J252D4) Brilliant Violet 605™ (top) or mouse IgG1, κ Brilliant Violet 605™ isotype control (bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

**Description:** CD185, also known as CXCR5, is a 42 kD G-protein coupled receptor with seven transmembrane regions. CXCR5 is expressed by mature B cells, follicular helper T cells, Burkitt's lymphoma cells and a subset of neurons, and mediates cell migration to the B cell follicles in the secondary lymphoid organs. The ligand of

CXCR5 is CXCL13 (BLC).

**Antigen  
References:**

1. Ma CS, *et al.* 2012. *J. Exp. Med.* 209:1241.
2. León B, *et al.* 2012. *Nat. Immunol.* 13:681.
3. Crotty S. 2011. *Annu. Rev. Immunol.* 29:621.
4. Kerfoot SM, *et al.* 2011. *Im*